TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer pain in outpatients with:~* Opioid based therapy due to pain~* Breakthrough pain or~* Extreme pain on movement~* Age \>= 18 years~Exclusion Criteria:~* Patients unable to give written informed consent~* Patients unable to understand how to handle and document the use of the study medication~* Known drug allergies or intolerance to ketamine~* Known drug allergies or intolerance to morphine~* Known allergy to crustacea or chitosan~* Patients using snuff at a regular basis~* Recreational drug addiction or abuse~* Serious intranasal or epipharyngeal Problems (Septum wall defects, cancer)~* Mental/psychiatric disorder~* Patients with renal failure (clearance \< 30 ml/min)~* Pregnancy and breast feeding mothers~* Patients not understanding German~* Patient having arterial hypertonia with measured values \> 180/95

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- morphine drops solo and placebo spray (Type: OTHER): morphine 2% drops~1. daily fixed dose of morphine equivalents \< 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards~2. daily fixed dose of morphine equivalents =/\> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards
- ketamine/chitosan spray nasal and placebo drops (Type: OTHER): 5 mg ketamine all 5 minutes, maximal 4 times an hour
- morphine drops and ketamine/chitosan spray nasal (Type: OTHER): see above

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Be associated with an NMDP/Be The Match-operated donor center or non-operated donor center that has an IRB Authorization Agreement with the NMDP IRB and allows NMDP staff to directly contact their donors~2. Possess an HLA haplotype of interest to the Study~3. Be at least 18 years of age and not past 61st birthday~4. Meet the following criteria and requirements:~4.1 Meet the donor requirements under 21 CFR 1271 and related August 2007 guidance 4.2 Body weight of at least 110 pounds 4.3 Complete and pass the abbreviated Health History Screening questionnaire 4.4 Complete and pass the full Health History questionnaire after donor enrollment 4.5 Non-reactive for any FDA-listed relevant communicable disease agent 4.6 Non-reactive for cytomegalovirus (CMV) 4.7 Express blood group O~Exclusion Criteria:~1. Be unwilling or unable to give informed consent~2. Be pregnant~3. Have a prior history of: (i) a bone marrow transplant, or (ii) cancer of any type

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 61 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre Bypass Ultrafiltration (PBUF) in Children Requiring Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients \< 8 kilograms and \< 1 year (to ensure that all patients receive steroids at initiation of CPB) undergoing an index cardiac operation for that hospitalization (using a single PBUF protocol)~Exclusion Criteria:~* Patients undergoing repeat cardiac surgery within the same admission~* Patients undergoing transplants as their index surgery~* Patients undergoing Ventricular assist device implantation as their index surgery

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard of care
- Study (Type: ACTIVE_COMPARATOR): PBUF used prior to Cardiopulmonary bypass

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proved diagnosis of colorectal cancer.~* Unresectable peritoneal metastases and primary tumor proved at surgery.~* No evidence of distant metastases.~* Have not received radiotherapy, chemotherapy or immunotherapy.~* ECOG score: 0\~2.~* Written informed consent is obtained prior to commencement of trial treatment.~Exclusion Criteria:~* Existence of distant metastasis outside the abdomen.~* Any previous radiotherapy, chemotherapy or immunotherapy.~* Active systemic infections.~* Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.~* Female patients who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with liver cirrhosis and ascites~* Meets all criteria for nosocomial SBP as outlined below~  * Ascitic fluid polymorphonuclear cells count \>250/mm3~ * Onset of signs and symptoms of infection after 72 hours of hospitalization~Exclusion Criteria:~* Hepatocellular carcinoma beyond the Milan criteria~* Abdominal surgery within 4 weeks~* Evidence of secondary peritonitis, pancreatitis or peritoneal carcinomatosis~* Significant heart or respiratory failure~* Allergy to ceftazidime, meropenem or daptomycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin + Meropenem (Type: EXPERIMENTAL): 30 patients with cirrhosis and nosocomial SBP
- Ceftazidime (Type: ACTIVE_COMPARATOR): 30 patients with cirrhosis and nosocomial SBP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study Between Bilateral and Unilateral Spinal Anaesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* spinal anaesthesia~* surgery\<60 minutes~Exclusion Criteria:~* preexisting micturition problems~* surgery lower abdomen/pelvis~* bmi\>30~* mental problems~* kidney disease~* neurologic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- bilateral spinal anesthesia (Type: EXPERIMENTAL): bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
- unilateral spinal anesthesia (Type: EXPERIMENTAL): unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult man or woman aged 18 years or greater.~* Clinical diagnosis of lateral epicondylitis based on site of pain, pain elicited with active extension of the wrist in pronation and elbow extension.~* Documented sonographic diagnosis of common extensor tendinosis based on tendon thickening, areas of hypoechogenicity, and loss of the normal echotexture.~* Chronic symptoms (equal or greater than 3 months).~* Pain of at least 5 out of 10 on a visual analog scale (VAS).~* Provision of informed consent.~Exclusion Criteria:~* Acute symptom onset (less than 2 months).~* History of acute elbow trauma (less than one week).~* History of rheumatoid arthritis.~* History of malignancy.~* Pregnancy~* Patients requiring anti-platelet medication for the treatment of heart attack, stroke or other medical condition.~* Previous surgery for lateral epicondylitis.~* Previous local injections, including steroids within the past 6 months.~* Signs of other causes for lateral elbow pain (posterior interosseous nerve entrapment, osteochondral lesion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Platelet Rich Plasma (PRP) Injection (Type: EXPERIMENTAL): Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
- Whole Blood Injection (Type: ACTIVE_COMPARATOR): Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
- Dry Needle Fenestration (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
- Sham Injection (Type: PLACEBO_COMPARATOR): Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: VSL#3 and Spontaneous Bacterial Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Male or Female, aged 18 years or above.~* Diagnosed with required disease/severity/symptoms as outlined in 6.3.1.~* Stable dose of current regular medication (e.g. diuretics, beta-blockers, vitamin supplementation) for at least 4 weeks prior to study entry.~* Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter~* Participants have clinically acceptable laboratory tests and ECG within 14 days of enrolment.~* Able (in the Investigators opinion) and willing to comply with all study requirements.~Willing to allow their General Practitioner and consultant~Exclusion criteria:~* Female participants who is pregnant, lactating or planning pregnancy during the course of the study.~* Presence of hepatocellular carcinoma~* Scheduled elective surgery or other procedures requiring general anaesthesia during the study.~* Participant who is terminally ill~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.~* Use of antibiotics or probiotics in the last 2 weeks~* Known hypersensitivity to trimethoprim, sulphonamides or any other ingredients in co-trimoxazole tablet.~* History of acute porphyria or serious haematological disorder.~* Participants who have participated in another research study involving an investigational product in the past 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Co-trimoxazole (Type: ACTIVE_COMPARATOR): Co-trimoxazole 960mg daily po
- VSL#3 active (Type: EXPERIMENTAL): VSL#3 active 2 sachets/daily
- VSL#3 placebo (Type: PLACEBO_COMPARATOR): VSL#3 placebo 2 sachets/daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Touch Massage in the Sub-acute Phase After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stroke defined according to Trial of ORG 10172 in Acute Stroke Treatment (TOAST) and The Oxford Community Stroke Project Classification (OSPC),~* impaired finger tapping on the affected side of the body,~* the ability to flex the wrist 20° from substrate on affected side of the body~Exclusion Criteria:individuals with~* cancerous tumors,~* infections with fever,~* neurologic or psychiatric disease,~* alcohol or drug addiction,~* conditions that impede communication.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Touch massage (Type: EXPERIMENTAL): Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
- non-TENS (Type: SHAM_COMPARATOR): The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anesthesia And Post-operative Mortality After Proximal Femur Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted wiht a diagnosis of proximal femur fracture (ICD-9 codes 820.0 to 820.9) and submitted to surgical internal fixation of femur or hip prosthesis (ICD-9 codes 7935, 8151 and 8152)~Exclusion Criteria:~* Multiple fractures; polytrauma, active malignancy, ASA(American Society of Anesthesia) status 5, antiplatelet drugs (other than aspirin) in the previous 5 days, known allergies to local anesthetics, contra-indication to general or regional anesthesia

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subarachnoid anesthesia (Type: ACTIVE_COMPARATOR): Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.~Up to 12.5 mg of bupivacaine or levobupivacaine will be used
- PNB/GA (Type: ACTIVE_COMPARATOR): Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~General:~A. Undergoing primary pacemaker implantation B. Able to appear for outpatient follow-up C. Age \> 18 years~Symptoms:~D. Syncope or E. Dizzy spells or F. Congestive heart failure~Electrocardiographic:~G. Sinus bradycardia \<40/minute for at least 1 minute in a conscious awake state or H. Sinus arrest/sinoatrial block \>2 seconds or I. Bradycardia/tachycardia with sinus-pauses \>2 seconds~Exclusion Criteria:~Clinical:~A. Malignant disease. B. Severe psychogenic disease including severe decrepitude and dementia. C. Impending larger operation expected to influence the major end point. D. Cardiac disorder expected to need cardiac surgery during the follow-up period.~E. Need for other device implantation: ICD (implantable cardioverter defibrillator) or implantable DC converter (for atrial fibrillation).~F. Carotid sinus syndrome (positive carotid sinus massage with pauses \>3 seconds).~Electrocardiographic:~G. Atrioventricular block. H. Bundle-branch block (complete RBBB, LBBB, bifascicular bundle-branch block or non-specific intraventricular block with QRS \>0.12 seconds).~I. Chronic atrial fibrillation. J. Atrial fibrillation/atrial flutter with QRS pauses \>3 seconds during atrial fibrillation.~K. Atrial fibrillation/atrial flutter with QRS frequency \<40/minute for 1 minute.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AAIR (Type: OTHER): None
- DDDR (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus since more than one year, treated by insulin since at least one year~* Treatment by insulin pump since at least 6 months~* Glycated hemoglobin (HbA1c) below 10.5% at inclusion visit~* For women of child bearing age, no current pregnancy and use of an efficient contraception during the whole research participation~* Agreement on no use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs, except if this therapy has been used for at least 3 months before study start~* Agreement on stopping closed-loop insulin delivery after acetaminophen use and 4 following hours~* Agreement on suspending use of patient CGM device during the study period while study CGM will be used~* Access to the internet and a mobile phone network at home~* Agreement on following study procedures~* Affiliation to the French social security system or a similar healthcare coverage system~* Mandatory written informed consent~Exclusion Criteria:~* Need for chronic use of acetaminophen~* Start of use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs during the 3 months before inclusion~* Hemophilia or other coagulation disorders~* Psychological and/or cognitive troubles which may impair the appropriate following of study procedures~* Diabetic ketoacidosis during the last 6 months~* Acute cardiovascular event during the last 12 months~* Severe hypoglycaemia with convulsions or loss of conscience during the last 12 months~* Use of a therapy with significant impact on glucose metabolism~* Cystic fibrosis~* Lack of nearby third-party assistance availability in case of troubles~* Malignant disease, except if considered as cured since at least 10 years~* Impaired kidney function (serum creatinin \> 150 umol/L)~* Impaired liver status (ALAT or ASAT \> 2-times upper normal limit)~* Active gastroparesis~* Acute adrenocortical event~* Alcohol or narcotics abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- insulin delivery driven by inControl (Type: EXPERIMENTAL): Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Same-day Dilapan-S With Adjunctive Misoprostol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years (no upper age limit)~* Gestational age between 16+0 and 20+6 weeks gestation on day of D\&E with confirmation of gestational age by ultrasound~* Desires D\&E for termination of pregnancy or for fetal demise~* Able to provide written informed consent~* Able to comply with study procedures~* English-speaking~Exclusion Criteria:~* Known allergy or contraindication to misoprostol~* Pregnancy with a multiple gestation~* Known bleeding disorder or current anticoagulation therapy (within one month of procedure)~* Active bleeding or hemodynamically unstable at enrollment~* Signs of chorioamnionitis or clinical infection at enrollment~* Signs of spontaneous labor or cervical insufficiency at enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): Misoprostol 400 mcg buccal 3 hours prior to D\&E as an adjunct to same-day Dilapan-S.
- Folic Acid (Type: PLACEBO_COMPARATOR): Folic acid 4 mg buccally 3 hours prior to D\&E as an adjunct to same-day Dilapan-S

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues